27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Amgen will pay Arrowhead $35 million upfront, invest $21.5 million in equity to gain exclusive license to ARC-LPA and a second option on an undisclosed second CV target of Arrowhead.
Amgen will also pay Arrowhead up to $617 million in development, option, regulatory, and commercial payments in to low double digit royalties for ARC-LPA and single digit royalties for its undisclosed target.
Cantor Fitzgerald reiterated its Buy rating and $15 price target on Arrowhead saying "we have not seen a deal with such favorable economics in recent history for a compound that is one to two years from the clinic."
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Meanwhile, Arrowhead took an edge over Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) in ALN-AAT program, an investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease.
Arrowhead's ALN-AAT program moved to Phase 1/2 trial with a clean safety profile at even higher doses, while Alnylam reported dose dependent liver enzyme elevations with doses from 3mg/ kg to 6mg/kg.
Analyst Elemer Piros does not see any liver safety concerns with Arrowhead's ARC-AAT, with shares of Alnylam falling as much as 8 percent to $70.58.
"Alnylam claims a sequence specific issue, but we cannot rule out a possibility that the issue is broader, chemistry-based for them. Regardless, Arrowhead is now clearly in the lead by at least 2–3 years with their AAT program," Piros wrote in a note.
At Time Of Writing ...
- Alnylam shares were down over 8 percent at $70.53.
- Amgen shares were at $167.46, down 1.33 percent.
- Arrowhead was up over 9 percent at $7.68.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.